MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL

Pigment Cell and Melanoma Research

Volumn 26, Issue 4, 2013, Pages 527-541

  Tworkoski, Kathryn A ^a   Platt, James T ^a   Bacchiocchi, Antonella ^a   Bosenberg, Marcus ^a   Boggon, Titus J ^a   Stern, David F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AXL; Melanoma; MERTK; Migration; Survival

Indexed keywords

PHOSPHOTRANSFERASE; PROTEIN AXL; PROTEIN CDC42; PROTEIN MERTK; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MELANOMA CELL MIGRATION; MUTATION; PATHOGENESIS; PROTEIN EXPRESSION; WILD TYPE;

CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYTOPHOTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MELANOMA; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84879786795     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12110     Document Type: Article

References (50)

1. Furdui, C.M., Lew, E.D., Schlessinger, J., and Anderson, K.S. (2006). Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell 21, 711-717.
2. Gal, A., Li, Y., Thompson, D.A., Weir, J., Orth, U., Jacobson, S.G., Apfelstedt-Sylla, E., and Vollrath, D. (2000). Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat. Genet. 26, 270-271.
3. Georgescu, M.M., Kirsch, K.H., Shishido, T., Zong, C., and Hanafusa, H. (1999). Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Mol. Cell. Biol. 19, 1171-1181.
4. Goydos, J.S., and Gorski, D.H. (2003). Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin. Cancer Res. 9, 5962-5967.
5. Greenman, C., Stephens, P., Smith, R. et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158.
6. Guttridge, K.L., Luft, J.C., Dawson, T.L., Kozlowska, E., Mahajan, N.P., Varnum, B., and Earp, H.S. (2002). Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J. Biol. Chem. 277, 24057-24066.
7. Gyorffy, B., and Lage, H. (2007). A Web-based data warehouse on gene expression in human malignant melanoma. J. Invest. Dermatol. 127, 394-399.
8. Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert, N., Schaerer, L., Hemmi, S., and Dummer, R. (2008). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650-656.
9. Holland, S.J., Powell, M.J., Franci, C. et al. (2005). Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res. 65, 9294-9303.
10. Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13.
11. Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
12. Huang, X., Finerty, P. Jr, Walker, J.R., Butler-Cole, C., Vedadi, M., Schapira, M., Parker, S.A., Turk, B.E., Thompson, D.A., and Dhe-Paganon, S. (2009). Structural insights into the inhibited states of the Mer receptor tyrosine kinase. J. Struct. Biol. 165, 88-96.
13. Hucthagowder, V., Meyer, R., Mullins, C., Nagarajan, R., Dipersio, J.F., Vij, R., Tomasson, M.H., and Kulkarni, S. (2012). Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma. Cancer Genet. 205, 474-478.
14. Keating, A.K., Kim, G.K., Jones, A.E. et al. (2010). Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol. Cancer Ther. 9, 1298-1307.
15. Kohn, A.D., Summers, S.A., Birnbaum, M.J., and Roth, R.A. (1996). Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 271, 31372-31378.
16. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
17. Lee, C.H., Yen, C.Y., Liu, S.Y., Chen, C.K., Chiang, C.F., Shiah, S.G., Chen, P.H., and Shieh, Y.S. (2011). Axl is a prognostic marker in oral squamous cell carcinoma. Ann. Surg. Oncol. 19, 500-508.
18. Leung, A.M., Hari, D.M., and Morton, D.L. (2012). Surgery for distant melanoma metastasis. Cancer J. 18, 176-184.
19. Li, L., Xiao, X., Li, S., Jia, X., Wang, P., Guo, X., Jiao, X., Zhang, Q., and Hejtmancik, J.F. (2011). Detection of variants in 15 genes in 87 unrelated Chinese patients with Leber congenital amaurosis. PLoS One 6, e19458.
20. Ling, L., and Kung, H.J. (1995). Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol. Cell. Biol. 15, 6582-6592.
21. Ling, L., Templeton, D., and Kung, H.J. (1996). Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase. J. Biol. Chem. 271, 18355-18362.
22. Linger, R.M., Keating, A.K., Earp, H.S., and Graham, D.K. (2008). TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35-83.
23. Linger, R.M., DeRyckere, D., Brandao, L., Sawczyn, K.K., Jacobsen, K.M., Liang, X., Keating, A.K., and Graham, D.K. (2009). Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood 114, 2678-2687.
24. Lu, Q., and Lemke, G. (2001). Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293, 306-311.
25. Lu, Q., Gore, M., Zhang, Q. et al. (1999). Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723-728.
26. Mahajan, N.P., and Earp, H.S. (2003). An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J. Biol. Chem. 278, 42596-42603.
27. Mannava, S., Grachtchouk, V., Wheeler, L.J., Im, M., Zhuang, D., Slavina, E.G., Mathews, C.K., Shewach, D.S., and Nikiforov, M.A. (2008). Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 7, 2392-2400.
28. Meerbrey, K.L., Hu, G., Kessler, J.D. et al. (2011). The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl Acad. Sci. USA 108, 3665-3670.
29. O'Bryan, J.P., Frye, R.A., Cogswell, P.C., Neubauer, A., Kitch, B., Prokop, C., Espinosa, R. 3rd, Le Beau, M.M., Earp, H.S., and Liu, E.T. (1991). axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11, 5016-5031.
30. Paccez, J.D., Vasques, G.J., Correa, R.G., Vasconcellos, J.F., Duncan, K., Gu, X., Bhasin, M., Libermann, T.A., and Zerbini, L.F. (2012). The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 32, 689-698.
31. Qi, J., Chen, N., Wang, J., and Siu, C.H. (2005). Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol. Biol. Cell 16, 4386-4397.
32. Qingxian, L., Qiutang, L., and Qingjun, L. (2010). Regulation of phagocytosis by TAM receptors and their ligands. Front. Biol. 5, 227-237.
33. Rankin, E.B., Fuh, K.C., Taylor, T.E., Krieg, A.J., Musser, M., Yuan, J., Wei, K., Kuo, C.J., Longacre, T.A., and Giaccia, A.J. (2010). AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 70, 7570-7579.
34. Rhodes, D.R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pandey, A., and Chinnaiyan, A.M. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
35. Riess, J.W., and Neal, J.W. (2011). Targeting FGFR, ephrins, Mer, MET, and PDGFR-alpha in non-small cell lung cancer. J. Thorac. Oncol. 6, S1797-S1798.
36. Samija, I., Lukac, J., Maric-Brozic, J., Buljan, M., Alajbeg, I., Kovacevic, D., Situm, M., and Kusic, Z. (2010). Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res. 20, 293-302.
37. Sayan, A.E., Stanford, R., Vickery, R. et al. (2012). Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene 31, 1493-1503.
38. Scolyer, R.A., Long, G.V., and Thompson, J.F. (2011). Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol. Oncol. 5, 124-136.
39. Seitz, H.M., Camenisch, T.D., Lemke, G., Earp, H.S., and Matsushima, G.K. (2007). Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J. Immunol. 178, 5635-5642.
40. Sensi, M., Catani, M., Castellano, G. et al. (2011). Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J. Invest. Dermatol. 131, 2448-2457.
41. Siegel, R., DeSantis, C., Virgo, K. et al. (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241.
42. Siemiatkowska, A.M., Arimadyo, K., Moruz, L.M. et al. (2011). Molecular genetic analysis of retinitis pigmentosa in Indonesia using genome-wide homozygosity mapping. Mol. Vis. 17, 3013-3024.
43. Tworkoski, K., Singhal, G., Szpakowski, S., Zito, C.I., Bacchiocchi, A., Muthusamy, V., Bosenberg, M., Krauthammer, M., Halaban, R., and Stern, D.F. (2011). Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol. Cancer Res. 9, 801-812.
44. Uhlen, M., Oksvold, P., Fagerberg, L. et al. (2010). Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 28, 1248-1250.
45. Vuoriluoto, K., Haugen, H., Kiviluoto, S., Mpindi, J.P., Nevo, J., Gjerdrum, C., Tiron, C., Lorens, J.B., and Ivaska, J. (2011). Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30, 1436-1448.
46. Wang, Y., Moncayo, G., Morin, P. Jr, Xue, G., Grzmil, M., Lino, M.M., Clement-Schatlo, V., Frank, S., Merlo, A., and Hemmings, B.A. (2012). Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32, 872-882.
47. Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, J.M. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
48. Wu, Y.M., Robinson, D.R., and Kung, H.J. (2004). Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res. 64, 7311-7320.
49. Xiong, W., Chen, Y., Wang, H., Wu, H., Lu, Q., and Han, D. (2008). Gas6 and the Tyro 3 receptor tyrosine kinase subfamily regulate the phagocytic function of Sertoli cells. Reproduction 135, 77-87.
50. Zhu, S., Wurdak, H., Wang, Y. et al. (2009). A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc. Natl Acad. Sci. USA 106, 17025-17030.